ZDA
MYGN icon

Zweig-DiMenna Associates’s Myriad Genetics MYGN Stock Holding History

Zweig-DiMenna Associates’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-8,600
Closed -$311K – 176
2017
Q3 		$311K Buy
+8,600
New +$245K 0.03% 136

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Zweig-DiMenna Associates's MYGN Position: Q4 2017 in Review

Zweig-DiMenna Associates sold out of Myriad Genetics (MYGN) in Q4 2017, closing a stake of 8,600 shares — an estimated $311K sold.

Zweig-DiMenna Associates first reported a position in MYGN in Q3 2017 and held it in 1 quarter. The position peaked at $311K in Q3 2017. 250 funds tracked by Wall St. Rank hold MYGN as of Q4 2017.

  • Zweig-DiMenna Associates reported no remaining Myriad Genetics position as of Q4 2017 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 8,600 Myriad Genetics shares in Q4 2017, an estimated $311K.
  • Zweig-DiMenna Associates first reported a position in Myriad Genetics in Q3 2017 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Myriad Genetics position peaked at $311K in Q3 2017.
  • 250 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2017.

Based on Zweig-DiMenna Associates's 13F filing for Q4 2017, filed 12 Feb 2018.